Adenosine A(2A) receptors in Parkinson's disease treatment.
about
Adenosine-associated delivery systemsCorrelation of transient adenosine release and oxygen changes in the caudate-putamen.Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson's disease: mitochondrial DNA integrity.Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.Deep brain stimulation of pallidal versus subthalamic for patients with Parkinson's disease: a meta-analysis of controlled clinical trials.Potential Role of Caffeine in the Treatment of Parkinson's Disease.An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders.Investigational approaches to therapies for restless legs syndrome.Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.The Adenosinergic System as a Therapeutic Target in the Vasculature: New Ligands and Challenges.[60]Fullerene derivative modulates adenosine and metabotropic glutamate receptors gene expression: a possible protective effect against hypoxia.Novel aspects of extracellular adenosine dynamics revealed by adenosine sensor cells.Commentary: Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism.Adenosine and its receptors as therapeutic targets: An overview.Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease.Antagonist binding and induced conformational dynamics of GPCR A2A adenosine receptor.Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease.Human Adenosine A2A Receptor: Molecular Mechanism of Ligand Binding and Activation.Unfolding Role of a Danger Molecule Adenosine Signaling in Modulation of Microbial Infection and Host Cell Response.Structural Connection between Activation Microswitch and Allosteric Sodium Site in GPCR Signaling.Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease.
P2860
Q26785351-38E46B95-C895-4DB1-B720-556A1BE9E20DQ30276561-DC5532F2-414A-4DCF-9E8E-CC03A250266AQ30438924-23D03F45-C844-4426-8F22-0E49441E97B5Q33645993-E62966A3-3E8C-4193-863E-52CF62A4B559Q34414817-80BF1C5D-874E-4FFC-A29D-226A3EDED810Q37042475-6BEF6D2B-CD71-4D64-8F83-E654A4C7F5BFQ37129378-729059E3-EBFB-44B1-90A2-2588B380C4DCQ37733587-C5F16482-352F-474F-8A4D-83E20C0915FCQ38202686-FEA50676-1A4A-4F09-989D-9E642DB7E802Q38237288-A2870D09-9E95-45E7-AC71-4F4AC03637C5Q38242390-C89323C5-832D-42D0-8F25-B318D9CD1837Q38686607-47743B04-401F-42A5-A29B-7FEE8117D80BQ38966000-3CD76C4D-AB9B-43AE-9810-083EC753E2B9Q41043672-D3B409B3-5809-4C72-A0D1-5F27D8230329Q41807583-7780F7BB-49FC-4EED-9576-7D48FC1DC280Q42059361-98ABCE11-A70C-46CC-ADF9-EF91505F10F6Q44311661-E6DBD6AF-5F4C-4269-8C7E-73F4EC9CEC5CQ45777876-9FA2D8B1-5BB1-4CDE-9DF5-6E25B1EEA7F5Q46168372-975B16D1-8E41-4134-8D7A-4F1D97793243Q47194737-65E6B6D7-77EC-4292-849B-8AC60A1E2B44Q48284423-3F4CF29D-06AA-4125-A037-E8CBDA8212E2Q50207906-547A79B9-984C-49FE-8411-E247C1926825Q54013959-50AAA85A-EDD8-4246-ACCA-34639AB4680E
P2860
Adenosine A(2A) receptors in Parkinson's disease treatment.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Adenosine A(2A) receptors in Parkinson's disease treatment.
@en
type
label
Adenosine A(2A) receptors in Parkinson's disease treatment.
@en
prefLabel
Adenosine A(2A) receptors in Parkinson's disease treatment.
@en
P2093
P2860
P1476
Adenosine A(2A) receptors in Parkinson's disease treatment.
@en
P2093
Andrzej Wojtczak
Marek Cieślak
Michał Komoszyński
P2860
P2888
P304
P356
10.1007/S11302-008-9100-8
P577
2008-04-26T00:00:00Z